

# Epilepsy - Pipeline Review, H1 2020

<https://marketpublishers.com/r/E045D88EDC0EN.html>

Date: February 2020

Pages: 605

Price: US\$ 2,000.00 (Single User License)

ID: E045D88EDC0EN

## Abstracts

Epilepsy - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epilepsy - Pipeline Review, H1 2020, provides an overview of the Epilepsy (Central Nervous System) pipeline landscape.

Epilepsy is a neurological disorder characterized by the transmission of abnormal signals produced by a group of neurons in the brain which causes seizures. This leads to brief disruptions of the senses and short periods of unconsciousness or convulsions. Symptoms of epilepsy are repeated seizures, weakness, and anxiety, loss of consciousness and contraction, or jerking, of body muscles. Main causes of epilepsy include low oxygen during birth, head injuries that occur during birth or from accidents during youth or adulthood, brain tumors, genetic conditions that result in brain injury, such as tuberous sclerosis, infections such as meningitis or encephalitis, and stroke or any other type of damage to the brain.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epilepsy - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Epilepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epilepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 8, 28, 25, 4, 93, 24 and 6 respectively. Similarly, the Universities portfolio in IND/CTA Filed, Preclinical and Discovery stages comprises 2, 23 and 3 molecules, respectively.

Epilepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Epilepsy (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Epilepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Epilepsy (Central

Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Epilepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Epilepsy (Central Nervous System)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Epilepsy (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Epilepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Epilepsy - Overview

Epilepsy - Therapeutics Development

Epilepsy - Therapeutics Assessment

Epilepsy - Companies Involved in Therapeutics Development

Epilepsy - Drug Profiles

Epilepsy - Dormant Projects

Epilepsy - Discontinued Products

Epilepsy - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Epilepsy, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Universities/Institutes, H1 2020  
Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Epilepsy - Pipeline by Aadi Bioscience Inc, H1 2020  
Epilepsy - Pipeline by Advanced Neural Dynamics Inc, H1 2020  
Epilepsy - Pipeline by Advicenne SA, H1 2020  
Epilepsy - Pipeline by Aequus Pharmaceuticals Inc, H1 2020  
Epilepsy - Dormant Projects, H1 2020  
Epilepsy - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Epilepsy, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

Aadi Bioscience Inc  
Advanced Neural Dynamics Inc  
Advicenne SA  
Aequus Pharmaceuticals Inc  
AfaSci Inc  
Affectis Pharmaceuticals AG  
AgoneX Biopharmaceuticals Inc  
AMO Pharma Ltd  
Anavex Life Sciences Corp  
Aphios Corp  
Aquestive Therapeutics Inc  
Asklepios BioPharmaceutical Inc  
Aucta Pharmaceuticals LLC  
Axium Pharmaceuticals Inc  
B&A Therapeutics  
BCWorld Pharm Co Ltd  
Benuvia Therapeutics Inc  
Bial - Portela & Ca SA  
Bio-Pharm Solutions Co Ltd  
Biogen Inc  
Bioinnotis

BioLink Life Sciences Inc  
Biovista Inc  
Bloom Science Inc  
Bristol-Myers Squibb Co  
Cann Pharmaceutical Australia Ltd  
Catalyst Pharmaceuticals Inc  
Cavion LLC  
Celavie Biosciences LLC  
Cellix Bio Pvt Ltd  
Cerebral Therapeutics Inc  
Cerecin Inc  
Cerevel Therapeutics LLC  
Coda Biotherapeutics Inc  
CombiGene AB  
Crossject SA  
CuroNZ Ltd  
CURx Pharmaceuticals Inc  
Cypralis Ltd  
Eisai Co Ltd  
Encoded Therapeutics Inc  
Engage Therapeutics Inc  
Epalex Corp  
EpyGenix Therapeutics Inc  
ES Therapeutics LLC  
Eton Pharmaceuticals Inc  
Ferring Pharmaceuticals Inc  
GABA Therapeutics Inc  
Genentech Inc  
Generoath Co Ltd  
Genus Lifesciences Inc  
Gilead Sciences Inc  
Glialogix Inc  
Guangzhou Cellprotek Pharmaceutical Co Ltd  
GW Pharmaceuticals Plc  
Harvest One Cannabis Inc  
Idorsia Pharmaceutical Ltd  
Ionis Pharmaceuticals Inc  
Iproteos SL  
JC Pharma Inc



Johnson & Johnson  
Karessa Pharma Holding AB  
Ketogen Inc  
Knopp Biosciences LLC  
LATITUDE Pharmaceuticals Inc  
Lead Discovery Center GmbH  
LifeSplice Pharma LLC  
Marinus Pharmaceuticals Inc  
Medicure Inc  
Medlab Clinical Ltd  
Mercaptor Discoveries Inc  
MGC Pharmaceuticals Ltd  
Mucodel Pharma LLC  
MyX Therapeutics Inc  
NeuCyte Inc  
NeurAegis Inc  
Neurelis Inc  
NeuroAdjuvants Inc  
Neurocrine Biosciences Inc  
NeuroCycle Therapeutics Inc  
Neuroene Therapeutics LLC  
NeuroLink, Inc  
Neuron Biopharma SA  
Neurona Therapeutics Inc  
New Amsterdam Sciences Inc  
Nissan Chemical Corp  
NoNO Inc  
NuBioPharma LLC  
OB Pharmaceuticals  
OPKO Health Inc  
Otsuka Holdings Co Ltd  
Ovid Therapeutics Inc  
OWP Pharmaceuticals Inc  
Painomix LLC  
Panaxia Pharmaceutical Industries Ltd  
Panorama Research Inc  
Pfizer Inc  
Pharmatrophix Inc  
Praxis Precision Medicines Australia Pty Ltd

Promius Pharma LLC  
Proniras Corp  
Proveca Ltd  
PTC Therapeutics Inc  
Recursion Pharmaceuticals Inc  
reMYND NV  
RogCon Inc  
Sage Therapeutics Inc  
Saniona AB  
Scientus Pharma Inc  
Sedor Pharmaceuticals LLC  
Serina Therapeutics Inc  
Simcere Pharmaceutical Group  
SK Biopharmaceuticals Co Ltd  
Stoke Therapeutics Inc  
Suda Pharmaceuticals Ltd  
Sumitomo Dainippon Pharma Co Ltd  
Sun Pharma Advanced Research Company Ltd  
Supernus Pharmaceuticals Inc  
Sustained Nano Systems LLC  
Taho Pharmaceuticals Ltd  
Takeda Pharmaceutical Co Ltd  
Techfields Pharma Co Ltd  
The Cell Factory BVBA  
Therapix Biosciences Ltd  
UCB SA  
Ultragenyx Pharmaceutical Inc  
Valerion Therapeutics LLC  
VistaGen Therapeutics Inc  
Vitality Biopharma Inc  
Xenon Pharmaceuticals Inc  
XERIS Pharmaceuticals Inc  
Xi'an Libang Pharmaceuticals Co Ltd  
XW Laboratories Inc  
Zhejiang Conba Pharmaceutical Co Ltd  
Zogenix Inc  
Zynerba Pharmaceuticals Inc

## I would like to order

Product name: Epilepsy - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/E045D88EDC0EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E045D88EDC0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970